TP53 and hepatocellular carcinoma: TP53 is the most frequently mutated gene in HCC patients (Yin et al., 2020), and early studies suggested that TP53 mutation was associated with the response to sorafenib for HCC patients (Gramantieri et al., 2020; Tang et al., 2020).